Cannabis Use in Adults with Neuropathic versus Non-Neuropathic Pain

Introduction: Cannabis has been decriminalized by many states and shows promise in treating both neuropathic and non-neuropathic pain through its interaction with the endocannabinoid system and anti-inflammatory effects. This study examines differences in cannabis use in adults with a primary condition of neuropathic versus non-neuropathic chronic pain. Materials and Methods: Cross-sectional survey data collected demographics and patient-reported outcomes including pain intensity and interference. Information regarding the type and frequency of cannabis-product use was also recorded. Participants were stratified into groups based on their most bothersome type of pain: neuropathic and non-neuropathic. Between group statistics assessed for differences. Results: Our sample consisted of 104 participants (61.5% female); with 36.5% reporting their most bothersome pain being neuropathic and 63.5% being non-neuropathic. Participants with neuropathic pain used cannabis and cannabis-based products significantly more days over the previous month and, when used, significantly more often per day. Discussion: This study found that adults with neuropathic pain used cannabis, especially Tetrahydrocannabinol-only (THC) and THC/Cannabidiol (CBD) combination products, more frequently than those with non-neuropathic pain. Those with neuropathic pain also reported higher levels of pain intensity and interference. Further longitudinal research is needed to confirm whether increased use of THC-rich cannabis provided symptom relief for adults with neuropathic pain.